Endoscopic ultrasound safety and efficacy in pediatric pancreatobiliary and gastrointestinal disorders: single-center retrospective trial.

IF 2 3区医学 Q2 PEDIATRICS

Frontiers in Pediatrics Pub Date : 2025-09-23 eCollection Date: 2025-01-01 DOI:10.3389/fped.2025.1684339

Jiayu Zhang, Zhaohui Deng

{"title":"Endoscopic ultrasound safety and efficacy in pediatric pancreatobiliary and gastrointestinal disorders: single-center retrospective trial.","authors":"Jiayu Zhang, Zhaohui Deng","doi":"10.3389/fped.2025.1684339","DOIUrl":null,"url":null,"abstract":"Background: While endoscopic ultrasound (EUS) is well established as a standard diagnostic and therapeutic tool in adults, its use in children remains limited. This study assessed the indications, safety, and clinical impact of diagnostic and therapeutic EUS in children with pancreatobiliary and gastrointestinal disorders.Methods: We retrospectively analyzed pediatric patients with pancreatobiliary and gastrointestinal disorders who underwent EUS at our institution between January 2022 and June 2025.Results: Fifty-three EUS procedures were conducted in children with a median age of 9.6 ± 3.0 years. Indications for EUS included acute recurrent pancreatitis (n = 15), suspected chronic pancreatitis (n = 12), suspected choledocholithiasis (n = 7), obstructive jaundice (n = 5), pancreatic mass (n = 1), gastric mucosal lesions (n = 6), suspected esophageal lymphoma recurrence (n = 1), suspected autoimmune hepatitis (n = 1) and pancreatic pseudocyst (PPC, n = 5). ERCP was performed during the same anesthesia for all children requiring it post-EUS. Five patients underwent cystogastrostomy for symptomatic PPC with 100% technical and clinical success. The efficacy of EUS in guiding definitive therapeutic decisions and invasive interventions was 100%. Notably, no major complications occurred.Conclusion: EUS is safe and effective diagnostic and therapeutic modality in pediatric patients with pancreatobiliary and gastrointestinal disorders.","PeriodicalId":12637,"journal":{"name":"Frontiers in Pediatrics","volume":"13 ","pages":"1684339"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12500564/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fped.2025.1684339","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: While endoscopic ultrasound (EUS) is well established as a standard diagnostic and therapeutic tool in adults, its use in children remains limited. This study assessed the indications, safety, and clinical impact of diagnostic and therapeutic EUS in children with pancreatobiliary and gastrointestinal disorders.

Methods: We retrospectively analyzed pediatric patients with pancreatobiliary and gastrointestinal disorders who underwent EUS at our institution between January 2022 and June 2025.

Results: Fifty-three EUS procedures were conducted in children with a median age of 9.6 ± 3.0 years. Indications for EUS included acute recurrent pancreatitis (n = 15), suspected chronic pancreatitis (n = 12), suspected choledocholithiasis (n = 7), obstructive jaundice (n = 5), pancreatic mass (n = 1), gastric mucosal lesions (n = 6), suspected esophageal lymphoma recurrence (n = 1), suspected autoimmune hepatitis (n = 1) and pancreatic pseudocyst (PPC, n = 5). ERCP was performed during the same anesthesia for all children requiring it post-EUS. Five patients underwent cystogastrostomy for symptomatic PPC with 100% technical and clinical success. The efficacy of EUS in guiding definitive therapeutic decisions and invasive interventions was 100%. Notably, no major complications occurred.

Conclusion: EUS is safe and effective diagnostic and therapeutic modality in pediatric patients with pancreatobiliary and gastrointestinal disorders.

Abstract Image

查看原文本刊更多论文

内镜超声治疗小儿胰胆和胃肠疾病的安全性和有效性：单中心回顾性试验。

背景：虽然内镜超声（EUS）作为成人的标准诊断和治疗工具已经建立，但其在儿童中的应用仍然有限。本研究评估了诊断性和治疗性EUS在患有胰胆和胃肠道疾病的儿童中的适应症、安全性和临床影响。方法：我们回顾性分析了2022年1月至2025年6月期间在我院接受EUS治疗的患有胰胆管和胃肠道疾病的儿童患者。结果：53例儿童行EUS手术，中位年龄9.6±3.0岁。EUS的适应症包括急性复发性胰腺炎（n = 15）、疑似慢性胰腺炎（n = 12）、疑似胆石结石（n = 7）、梗阻性黄疸（n = 5）、胰腺肿块（n = 1）、胃粘膜病变（n = 6）、疑似食管淋巴瘤复发（n = 1）、疑似自身免疫性肝炎（n = 1）、胰腺假性囊肿（PPC, n = 5）。所有在eus后需要ERCP的儿童在相同的麻醉下进行ERCP。5例患者因症状性PPC行膀胱胃造口术，技术和临床成功率均为100%。EUS在指导明确的治疗决策和侵入性干预方面的有效性为100%。值得注意的是，没有发生重大并发症。结论：EUS是一种安全有效的诊断和治疗小儿胰胆和胃肠疾病的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Pediatrics Medicine-Pediatrics, Perinatology and Child Health

CiteScore

3.60

自引率

7.70%

发文量

2132

审稿时长

14 weeks

期刊介绍： Frontiers in Pediatrics (Impact Factor 2.33) publishes rigorously peer-reviewed research broadly across the field, from basic to clinical research that meets ongoing challenges in pediatric patient care and child health. Field Chief Editors Arjan Te Pas at Leiden University and Michael L. Moritz at the Children''s Hospital of Pittsburgh are supported by an outstanding Editorial Board of international experts. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Pediatrics also features Research Topics, Frontiers special theme-focused issues managed by Guest Associate Editors, addressing important areas in pediatrics. In this fashion, Frontiers serves as an outlet to publish the broadest aspects of pediatrics in both basic and clinical research, including high-quality reviews, case reports, editorials and commentaries related to all aspects of pediatrics.